Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024 ...

Turning the human body into a biofactory of precision protein therapeutics is the focus of newly launched Signify Bio, which ...

Researchers from the University of Arizona have unveiled that coordinated Y chromosome loss in both cancer cells and immune ...

Aiatella Oy secured €2 million (US$2.28 million) in funding for its AI-powered cardiovascular imaging technology. The funds ...

A publication based on longitudinal and cross sectional data and led by researchers at the U.S. NIH’s National Institute on ...

Researchers at ETH Zürich developed Menstruai, a device that detects in menstruation blood biomarkers associated with certain ...

In yet another China antibody-drug conjugate (ADC) deal, Astellas Pharma Inc. is inlicensing a phase I/II ADC targeting Claudin 18.2 from Evopoint Biosciences Co. Ltd. for up to $1.34 billion.

Biopharma financings totaled $21.38 billion through May 2025, down sharply from $62.57 billion during the same period in 2024, but roughly in line with levels seen in 2023 and 2022. Biopharma ...

The EMA has issued a new guideline on how to include and/or retain pregnant and breastfeeding women in clinical trials, in a ...

Human adenovirus may cause severe infections in both immunosuppressed and immunocompetent individuals and there is no ...

Rakuten Medical Inc.’s RM-0256 has been selected for funding by Japan’s Agency for Medical Research and Development (AMED).

In the midst of June’s peak wedding season, Highridge Medical LLC called it splitsville – selling its bone healing division ...